Результаты поиска

Primary hyperparathyroidism-induced brown tumors caused by parathyroid carcinoma: a case report and literature review

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Distribution and features of hematological malignancies in Eastern Morocco: a retrospective multicenter study over 5 years.

BackgroundHematological malignancies (HM) are a public health problem. The pattern and distribution of diagnosed hematological cancers vary depending on age, sex, geography, and ethnicity suggesting the involvement of genetic and environmental factors for the development of these diseases. To our knowledge, there is no published report on HM in the case of Eastern Morocco. In this report we present for the first time the overall pattern of HM for this region.MethodsRetrospective descriptive study of patients diagnosed with HM between January 2008 and December 2012 in three centres in Eastern M

Предлагаемый протокол наблюдений для ранней дифференциации синдрома высвобождения цитокина и сепсиса в реципиентах CAR-T с гематологическими аномалиями с использованием IL-6Соотношение ПХТ: исследование ДРАКАРИС.

Терапия антигенного рецептора T-клеток (CAR-T) произвела революцию в лечении гематологических магнатов, продемонстрировав замечательную эффективность в лейкемиях B-клеток, лимфомах и множестве миелом. Однако синдром сильного токсина, особенно синдрома цитокина (CRS) и сепсиса, сопряженный с серьезными клиническими проблемами. Оба эти условия имеют совпадающие черты, включая лихорадку, гипотенцию и многоорганическую дисфункцию, что делает важную роль своевременной и точной дифференциации. В основе ДУС лежит чрезмерное высвобождение цитокина, главным образом IL-6, и лечится IL-6 Блокада рецептор

FOXM1 contributes to treatment failure in acute myeloid leukemia.

Acute myeloid leukemia (AML) patients with NPM1 mutations demonstrate a superior response to standard chemotherapy treatment. Our previous work has shown that these favorable outcomes are linked to the cytoplasmic relocalization and inactivation of FOXM1 driven by mutated NPM1. Here, we went on to confirm the important role of FOXM1 in increased chemoresistance in AML. A multiinstitution retrospective study was conducted to link FOXM1 expression to clinical outcomes in AML. We establish nuclear FOXM1 as an independent clinical predictor of chemotherapeutic resistance in intermediate-risk AML i

Конвергенция генетики вируса хост и Эпштейн-Барр в множестве склерозов.

Недавние сероэпидемиологические исследования укрепили гипотезу о том, что вирус Эпштейн-Барр (ЭБВ) может быть причиной множественного склероза (МС). С учетом сложности взаимодействия EBV-принимателя различные механизмы могут нести ответственность за патогенез болезни. Кроме того, остается неясным, относится ли это к конкретным заболеваниям. Здесь мы показали, что гены, кодирующие взаимодействие EBV, обогащаются в лоси, связанных с MS, но не с другими заболеваниями и в приоритетных терапевтических целях. Анализ крови MS и транскриптомов мозга подтвердил дисрегулирование связанных с MS EBV интер

Efficacy and safety of venous angioplasty of the extracranial veins for multiple sclerosis. Brave dreams study (brain venous drainage exploited against multiple sclerosis): study protocol for a randomized controlled trial.

BackgroundMultiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system with a disabling progressive course. Chronic cerebrospinal venous insufficiency (CCSVI) has recently been described as a vascular condition characterized by restricted venous outflow from the brain, mainly due to blockages of the internal jugular and azygos veins. Despite a wide variability among studies, it has been found to be associated with MS. Data from a few small case series suggest possible improvement of the clinical course and quality of life by performing percutaneous ball

62nd Annual Conference of the Indian Society of Gastroenterology, February 10th - 13th, 2022, Pune.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… King’s college criteria and Kochi criteria (model for end-stage liver disease [MELD] score ≥36 or baseline international normalized ratio [INR] ≥ 6 with hepatic encephalopathy) (Saraf et al. PMID: 26310868) were used to assess need for urgent liver transplantation. …

Bidireкционная связь между системным иммунно-воспалительным индексом и анемией после аутологичной трансплантации стволовых клеток у пациентов с мультиплексной миеломой: ретроспективное когорта исследование.

БАКGROUND: Автологическая трансплантация стволовых клеток (АСК) является ключевой терапией для консолидации при множественной миеломе (ММ). Однако анемия после трансплантации является распространенной осложнением, которое нарушает восстановление и прогноз. Системный иммунно-воспалительный индекс (СИИ), удобный показатель системного воспалительного бремени, связан с прогнозом в различных опухолях. Настоящее исследование направлено на изучение двунаправленной связи между СИИ до АСК и анемией после АСК у пациентов с ММ, определение прогнозной ценности СИИ для анемии и исследование влияния базовой

Моноклональная гаммопатия как потенциальная причина чистой красной клетки Aplasia: Case Report and Literic Review.

Ранее сообщалось, что чисто красные клетки аплазии (ПРКА) являются вторичными по сравнению с плазменными клеточными дискразиями; однако эти случаи редки и зачастую не имеют клинических деталей. Здесь мы сообщаем о случае 44-year-old Женщина-пациентка с прогрессивной нормоцитической анемией при установлении монокланской гаммопатии IgG-kappa без соблюдения диагностических критериев для множественной миеломы или любой другой гематологической злокачественности. Несмотря на то, что первоначальная диагностика ПОПР была безрезультатной, и несмотря на переходную реакцию на эритропоизизизуализирующие в

Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients.

Early morbidity and mortality affect patient outcomes in multiple myeloma. Thus, we dissected the incidence and causes of morbidity/mortality during induction therapy (IT) for newly diagnosed multiple myeloma (NDMM), and developed/validated a predictive risk score. We evaluated 3700 transplant-eligible NDMM patients treated in 2005-2020 with novel agent-based triplet/quadruplet IT. Primary endpoints were severe infections, death, or a combination of both. Patients were divided in a training (n = 1333) and three validation cohorts (n = 2367). During IT, 11.8%, 1.8%, and 12.5% of patients in the

The Relationship between Changes in Serum Element Concentrations and Pathological Condition and Disease Status in Japanese Multiple Myeloma Patients: A Pilot Study and Literature Review.

BackgroundMultiple myeloma (MM) is a rare cancer, and information on its pathological condition and serum element levels is lacking. In this pilot study, we examined serum element concentrations in Japanese patients with MM by a comprehensive multi-element analysis.MethodsThis is a case-control study of 12 Japanese patients diagnosed with MM at the Nagoya City University Hospital between 2008 and 2013. Blood samples were taken, at the initial diagnosis and at relapse. The serum concentrations of 12 elements were analyzed by inductively coupled plasma mass spectrometry and compared between MM p

Anti-Tumor Effects of Low Dose Zoledronate on Lung Cancer-Induced Spine Metastasis.

Zoledronate (Zol) is an anti-resorptive/tumoral agent used for the treatment of many cancers including spinal bone metastasis. High systemic administration of a single dose is now the standard clinical care, yet it has been associated with several side effects. Here, we aimed to evaluate the effects of lower doses Zol on lung cancer and lung cancer-induced bone metastasis cells over a longer time period. Human lung cancer (HCC827) and three bone metastases secondary to lung cancer (BML1, BML3 and BML4) cells were treated with Zol at 1, 3 and 10 µM for 7 days and then assessed for cell prolifer

Low hemoglobin as a novel prognostic biomarker in EBV-positive diffuse large B-cell lymphoma patients: a clinical feature analysis of 99 cases from Zhejiang, Southeast China.

Epstein-Barr virus-positive diffuse large B-cell lymphoma (EBV+DLBCL) is a rare and clinically aggressive subtype of DLBCL, distinguished by its notably unfavorable prognosis. The clinical characteristics of this entity remain insufficiently characterized in the Chinese population. This study retrospectively analyzed 99 cases of EBV+DLBCL with available clinical data from Zhejiang Province, southeastern China. We comprehensively characterized the clinicopathological features of these patients and performed both univariate and multivariate survival analyses to identify independent prognostic fa

A cost-utility and budget impact analysis of allogeneic hematopoietic stem cell transplantation for severe thalassemic patients in Thailand.

BackgroundHematopoietic stem cell transplantation (HSCT) is the only curative treatment available to severe thalassemic patients. The treatment, however, is very costly, particularly in the context of low and middle income countries, and no studies have been carried out to explore its economic justifiability. This study aimed to estimate the cost-utility of HSCT compared with blood transfusions combined with iron chelating therapy (BT-ICT) for severe thalassemia in Thailand, and to investigate the affordability of HSCT using a budget impact analysis.MethodsA Markov model was used to estimate t

2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde.

According to the updated International Myeloma Working Group criteria, smoldering multiple myeloma (SMM) is an asymptomatic plasma cell disorder characterized by an M-component >3 g/dL, bone marrow plasma cell infiltration >10% and <60%, and absence of any myeloma-defining event. Active multiple myeloma is preceded by SMM, with a median time to progression of approximately 5 years. Cases of SMM range from the extremes of "monoclonal gammopathy of undetermined significance-like", in which patients never progress during their lifetimes, to "early multiple myeloma", in which transformation into s

Реналь-лимитированный амилоидный лайт-чаин (Ламбда) Амилоидоз, представленный как Моноклональная Гаммопатия Ренального Значения: доклад по делу.

Моноклональная гаммопатия почечной значимости (MGRS) охватывает почечные заболевания, вызываемые нефротоксичными моноклональными иммуноглобулинами, производимыми небольшими клонами B-клеток или плазменными клонами, которые не отвечают критериям явной гематологической злокачественности. Ренал амилоидный светоцепный (AL) амилоидоз — признанное повреждение в диапазоне MGRS. Мы сообщаем о случае 66-year-old Женщина с нефротическим синдромом и почечной дисфункцией, связанными с моноклональными лямбдами. Биопсия реала подтвердила амилоидоз AL (ламбда), в то время как анализ костного мозга и системна

If It's Not One Thing, It's Another: An Inverse Relationship of Malignancy and Atherosclerotic Disease.

Atherosclerosis and malignancy are pervasive pathological conditions that account for the bulk of morbidity and mortality in developed countries. Our current understanding of the patholobiology of these fundamental disorders suggests that inflammatory processes may differentially affect them; thus, atherosclerosis can be largely driven by inflammation, where as cancer often flourishes as inflammatory responses are modulated. A corollary of this hypothesis is that cancer (or its treatment may significantly attenuate atherosclerotic disease by diminishing host inflammatory response, suggesting p

Abstract

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an ad hoc expert panel.

The introduction of new therapeutic agents for multiple myeloma (MM), including proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies, has improved the outcomes of patients but, in parallel, has changed the frequency and epidemiology of thrombotic events. Thrombosis is now a significant cause of morbidity and mortality in MM patients, and optimal thromboprophylaxis is far from being reached. Moving from the recognition that the above issue represents an unmet clinical need, an expert panel assessed the scientific literature and composed a framework of recommendations for imp

Совпадение в полном тексте источника
… Full-dose warfarin to maintain a therapeutic International Normalized Ratio of 2–3 is an alternative to MWH. 7 In 2015, the European Myeloma Network provided recommendations for the management of the most common complications of MM. … For those with an IMPEDE score of ≥4 points or a SAVED score of ≥2 points, the recommendation is enoxaparin (40 mg/day subcutaneously), warfarin (target International Normalized Ratio, 2.0–3.0), fondaparinux (2.5 mg/day sub-cutaneously), or a DOAC, such as rivaroxaban at a dose of 10 mg/day orally or …

Population pharmacokinetic/pharmacodynamic joint modeling of ixazomib efficacy and safety using data from the pivotal phase III TOURMALINE-MM1 study in multiple myeloma patients.

Ixazomib is an oral proteasome inhibitor approved in combination with lenalidomide and dexamethasone for the treatment of relapsed/refractory multiple myeloma (MM). Approval in the United States, Europe, and additional countries was based on results from the phase III TOURMALINE-MM1 (C16010) study. Here, joint population pharmacokinetic/pharmacodynamic time-to-event (TTE) and discrete time Markov models were developed to describe key safety (rash and diarrhea events, and platelet counts) and efficacy (myeloma protein [M-protein] and progression-free survival [PFS]) outcomes observed in TOURMAL